Gregory Renza
Stock Analyst at RBC Capital
(3.13)
# 1,224
Out of 4,983 analysts
207
Total ratings
39.79%
Success rate
2.99%
Average return
Main Sectors:
Stocks Rated by Gregory Renza
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Outperform | $31 → $35 | $64.75 | -45.95% | 3 | May 23, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Outperform | $26 | $23.97 | +8.47% | 16 | May 19, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Outperform | $8 | $3.31 | +141.69% | 12 | May 15, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Sector Perform | $5 | $2.28 | +119.30% | 11 | May 14, 2025 | |
| EXEL Exelixis | Reiterates: Outperform | $40 | $39.15 | +2.17% | 10 | May 14, 2025 | |
| ONC BeOne Medicines AG | Maintains: Outperform | $312 → $311 | $326.17 | -4.65% | 2 | May 8, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $182 → $172 | $126.43 | +36.04% | 14 | May 7, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $35 → $32 | $6.95 | +360.76% | 3 | May 2, 2025 | |
| AMGN Amgen | Maintains: Outperform | $324 → $320 | $273.02 | +17.21% | 17 | May 2, 2025 | |
| CGON CG Oncology | Maintains: Outperform | $66 → $68 | $35.76 | +90.16% | 3 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $15 | $3.28 | +357.32% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $11.59 | +3.54% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $9.18 | +52.59% | 10 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $32 | $8.61 | +271.88% | 9 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $27 | $8.47 | +218.77% | 11 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $24.69 | +147.06% | 12 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $18 | $26.53 | -32.15% | 11 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $48 | $2.44 | +1,867.21% | 4 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 → $10 | $3.28 | +205.34% | 6 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $7 → $10 | $5.38 | +86.05% | 1 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $47 | $18.65 | +152.01% | 11 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $57 | $36.60 | +55.74% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $7.33 | -45.43% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $110 → $20 | $4.43 | +351.47% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $1.08 | +1,388.37% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $2,160 → $180 | $9.73 | +1,749.95% | 4 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $100 → $80 | $1.44 | +5,455.56% | 5 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $105 → $30 | $0.68 | +4,327.72% | 3 | Jun 2, 2020 |
Cidara Therapeutics
May 23, 2025
Maintains: Outperform
Price Target: $31 → $35
Current: $64.75
Upside: -45.95%
ACADIA Pharmaceuticals
May 19, 2025
Reiterates: Outperform
Price Target: $26
Current: $23.97
Upside: +8.47%
ADC Therapeutics
May 15, 2025
Reiterates: Outperform
Price Target: $8
Current: $3.31
Upside: +141.69%
Inovio Pharmaceuticals
May 14, 2025
Reiterates: Sector Perform
Price Target: $5
Current: $2.28
Upside: +119.30%
Exelixis
May 14, 2025
Reiterates: Outperform
Price Target: $40
Current: $39.15
Upside: +2.17%
BeOne Medicines AG
May 8, 2025
Maintains: Outperform
Price Target: $312 → $311
Current: $326.17
Upside: -4.65%
Jazz Pharmaceuticals
May 7, 2025
Maintains: Outperform
Price Target: $182 → $172
Current: $126.43
Upside: +36.04%
Bicycle Therapeutics
May 2, 2025
Maintains: Outperform
Price Target: $35 → $32
Current: $6.95
Upside: +360.76%
Amgen
May 2, 2025
Maintains: Outperform
Price Target: $324 → $320
Current: $273.02
Upside: +17.21%
CG Oncology
Apr 29, 2025
Maintains: Outperform
Price Target: $66 → $68
Current: $35.76
Upside: +90.16%
Mar 27, 2025
Maintains: Outperform
Price Target: $16 → $15
Current: $3.28
Upside: +357.32%
Mar 26, 2025
Reiterates: Outperform
Price Target: $12
Current: $11.59
Upside: +3.54%
Mar 21, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $9.18
Upside: +52.59%
Feb 27, 2025
Maintains: Outperform
Price Target: $34 → $32
Current: $8.61
Upside: +271.88%
Jan 29, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $8.47
Upside: +218.77%
Jan 15, 2025
Reiterates: Outperform
Price Target: $61
Current: $24.69
Upside: +147.06%
Jan 14, 2025
Reiterates: Sector Perform
Price Target: $18
Current: $26.53
Upside: -32.15%
Jan 9, 2025
Maintains: Outperform
Price Target: $68 → $48
Current: $2.44
Upside: +1,867.21%
Jan 7, 2025
Reiterates: Outperform
Price Target: $6 → $10
Current: $3.28
Upside: +205.34%
Dec 19, 2024
Upgrades: Outperform
Price Target: $7 → $10
Current: $5.38
Upside: +86.05%
Dec 17, 2024
Maintains: Outperform
Price Target: $44 → $47
Current: $18.65
Upside: +152.01%
Dec 10, 2024
Maintains: Outperform
Price Target: $55 → $57
Current: $36.60
Upside: +55.74%
Nov 14, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $7.33
Upside: -45.43%
Nov 5, 2024
Downgrades: Sector Perform
Price Target: $110 → $20
Current: $4.43
Upside: +351.47%
Aug 14, 2024
Reiterates: Outperform
Price Target: $16
Current: $1.08
Upside: +1,388.37%
Jun 27, 2023
Downgrades: Sector Perform
Price Target: $2,160 → $180
Current: $9.73
Upside: +1,749.95%
Mar 16, 2022
Maintains: Sector Perform
Price Target: $100 → $80
Current: $1.44
Upside: +5,455.56%
Jun 2, 2020
Downgrades: Sector Perform
Price Target: $105 → $30
Current: $0.68
Upside: +4,327.72%